相关实验视频

Updated: May 12, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 19, 2013

BCR::ABL1 美国慢性阶段慢性髓性白血病患者的突变剖析,使用氨酸激酶抑制剂

Fadi G Haddad¹, Elias J Jabbour¹, Stephen W Gutkin²

¹Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.

Cancer diagnosis & prognosis

|March 4, 2026

概括

在慢性髓性白血病 (CML) 患者的BCR::ABL1突变分析中,治疗反应的差异很小. 然而,接受这种测试的患者更有可能患有腹壮成症,这表明潜在的准则遵守问题.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子诊断学分子诊断学

背景情况:

铁氨酸激酶抑制剂 (TKIs) 转化慢性髓性白血病 (CML) 治疗.
BCR::ABL1突变导致TKI耐药性,使患者的护理复杂化.
在美国社区环境中,BCR::ABL1突变分析的现实实践没有得到充分的记录.

研究的目的:

评估美国社区血液学和瘤学实践中BCR::ABL1突变分析的现实实践.
评估BCR::ABL1突变分析对临床决策和CML患者结局的影响.

主要方法:

在枢机病瘤医疗服务提供商扩展网络 (OPEN) 中进行了回顾性图表审查.
13位血液学家/瘤学家审查了成年慢性阶段CML患者的病历.
患者被分为两个队列:接受BCR::ABL1激酶域突变概况分析 (n=26) 和未接受BCR:ABL1激酶域突变概况分析 (n=25) 的患者.

主要成果:

在具有或没有突变分析的患者之间,没有观察到分子测试失败或警告信号的显著差异.
在两组中,最佳临床里程碑的频率相似.
接受BCR::ABL1突变分析的患者显著更有可能出现腹壮大 (p=0.0069).

结论:

在接受和不接受BCR::ABL1突变分析的患者之间,在治疗响应标志物中发现了很少的显著差异.
在分析组中,壮症的可能性增加,尽管这不是指导方针指示的测试原因,但引起了人们的担忧.
调查结果表明,与共识指导方针的潜在偏差,影响TCI耐药性的最佳CML管理.

关键词:

BCR::ABL1 的意思慢性骨髓性白血病慢性骨髓性白血病突变是一种突变.审查审查审查审查审查审查治疗抵抗性的治疗.铁氨基激酶抑制剂铁氨基激酶抑制剂

更多相关视频

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...